FDA approves Boston Scientific leads for left bundle branch area pacing Posted on September 18th, 2024 by LEADconnection Post navigation Previous: Lumenless and Stylet-Driven Leads for Left Bundle Branch Area Pacing: Materials, Techniques, Benefits, and Trade-Offs of the Two Approaches.Next: LBBAP limits hospital readmissions after TAVR
FDA approves Biotronik lead, catheter for left bundle branch area pacing Posted on September 16th, 2024 by LEADconnection Post navigation Previous: BIOTRONIK Receives FDA Approval for LBBAP Indication on Pacing Lead and Delivery Catheter SystemNext: Cardiac implantable electronic device infection awareness – A European survey amongst implanting physicians
Biotronik receives CE mark for Amvia Sky and Edge devices Posted on July 1st, 2024 by LEADconnection Post navigation Previous: FDA clears new drug-eluting envelope for implantable cardiac devices—CEO sees it as ‘tip of the iceberg’Next: Outcomes of combined left bundle branch area pacing with atrioventricular nodal ablation in patients with atrial fibrillation and pulmonary disease